Historical Bulking Agents
These pages cover older or experimental urologic injections and their relevance when evaluating previously treated patients. The individual articles distinguish historical efficacy reports, safety findings and current treatment options.
| Material | Main reason to revisit the history |
|---|---|
| Teflon (PTFE / Polytef) | Persistent particles, migration and delayed foreign-body masses after incontinence or reflux treatment. |
| Contigen (GAX-collagen) | Prior bovine-collagen injections, declining continence benefit and agent-specific reactions. |
| Autologous Fat | Failed historical urethral-bulking approach with a fatal embolism in its placebo-controlled trial; distinguish it from cell-based research. |
| Autologous Chondrocytes | Experimental cultured-cartilage implants, their durability and late imaging findings. |
Evaluation After Prior Injection
Document the agent, injection site, timing, repeat treatments and subsequent operations when possible. Current symptoms may reflect recurrent incontinence or reflux, obstruction, inflammation, infection, retained material or an unrelated problem. A visible implant does not by itself establish its function or explain every symptom.
Prior injection alone does not settle eligibility for further reconstruction. Assess tissue quality, obstruction, infection and the planned operation; symptomatic masses or fibrosis can alter the approach. Use the relevant device and clinical pathway rather than an old injection recipe.
See also: Bulkamid, Macroplastique, Deflux, Incontinence Procedures.